Prognostic Value of Cardiac Biomarkers Assessment in Combination with Myocardial 2D Strain Echocardiography for Early Detection of Anthracycline-Related Cardiac Toxicity

Author(s): Mohammad P. Mahjoob, Seyed A. Sheikholeslami, Morvarid Dadras, Hamdollah Mansouri, Mahshid Haghi, Mohammadreza Naderian, Leila Sadeghi, Mohammadreza Tabary*, Isa Khaheshi*

Journal Name: Cardiovascular & Hematological Disorders-Drug Targets
Formerly Current Drug Targets - Cardiovascular & Hematological Disorders

Volume 20 , Issue 1 , 2020

DOI : 10.2174/1871529X19666190912150942

  Journal Home
Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Anthracyclines, a widely used chemotherapy agent with a definite survival improvement, can result in cardiac toxicity presenting with HF (heart failure).

Objective: We aim to assess the predictive value of cardiac biomarkers assessment in combination with myocardial two-dimensional strain echocardiography for early detection of cardiac toxicity in patients who underwent Anthracycline-based chemotherapy.

Methods: Fifty-two consecutive adult patients scheduled to undergo the first course of Anthracycline-based chemotherapy were subjected to the study. All the patients underwent highly sensitive 2D echocardiographic evaluation before the treatment, 4 and 12 weeks after completion of first-course chemotherapy. Longitudinal and segmental strains were measured. Serum levels of High-sensitive cardiac troponin I (hscTn-I) and N-terminal-pro-BNP (NT-proBNP) were also assessed before the initiation and 3 weeks after completion of first-course chemotherapy.

Results: Fifteen patients (28.8%) revealed a decrease in LVEF (Left Ventricular Ejection Fraction) throughout the evaluations, while just 5 patients met the criteria of cardiac toxicity (9.6%). AUC for Global Longitudinal Strain (GLS) ROC curve at 4 weeks of follow-up was calculated to be 0.968. Inferoseptal Systolic Longitudinal Strain (SLS) had the highest AUC value (AUC: 0.934) among different wall SLS. LVESD (Left Ventricular End-Systolic Diameter) at first and second evaluation could predict the risk of cardiac toxicity among LVESD, LVEDD (Left Ventricular End Diastolic Diameter) and LVEDV (Left Ventricular End-Diastolic Volume). Among cardiac biomarkers, hscTnI had higher sensitivity, while NT-proBNP had higher specificity for cardiac toxicity.

Conclusion: This study has shown that hs-cTnI with good sensitivity can predict cardiac toxicity in Anthracycline-based chemotherapy receiver. The use of strain with speckle echocardiography method has a prognostic value; however, both longitudinal and segmental strain should be assessed. Lateral and inferoseptal SLS (Segmental Longitudinal Strain) are specific markers of cardiac toxicity in the course of anthracycline-related cardiac toxicity.

Keywords: Anthracyclines, cardiotoxicity, echocardiography, heart failure, biomarkers, cardiovascular diseases.

[1]
Oeffinger, K.C.; Mertens, A.C.; Sklar, C.A.; Kawashima, T.; Hudson, M.M.; Meadows, A.T.; Friedman, D.L.; Marina, N.; Hobbie, W.; Kadan-Lottick, N.S.; Schwartz, C.L.; Leisenring, W.; Robison, L.L.; Childhood Cancer Survivor, S. Childhood Cancer Survivor Study. Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med., 2006, 355(15), 1572-1582.
[http://dx.doi.org/10.1056/NEJMsa060185] [PMID: 17035650]
[2]
Mertens, A.C.; Yasui, Y.; Neglia, J.P.; Potter, J.D.; Nesbit, M.E., Jr; Ruccione, K.; Smithson, W.A.; Robison, L.L. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J. Clin. Oncol., 2001, 19(13), 3163-3172.
[http://dx.doi.org/10.1200/JCO.2001.19.13.3163] [PMID: 11432882]
[3]
Singal, P.K.; Iliskovic, N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med., 1998, 339(13), 900-905.
[http://dx.doi.org/10.1056/NEJM199809243391307] [PMID: 9744975]
[4]
Diller, L.; Chow, E.J.; Gurney, J.G.; Hudson, M.M.; Kadin-Lottick, N.S.; Kawashima, T.I.; Leisenring, W.M.; Meacham, L.R.; Mertens, A.C.; Mulrooney, D.A.; Oeffinger, K.C.; Packer, R.J.; Robison, L.L.; Sklar, C.A. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J. Clin. Oncol., 2009, 27(14), 2339-2355.
[http://dx.doi.org/10.1200/JCO.2008.21.1953] [PMID: 19364955]
[5]
Carver, J.R.; Shapiro, C.L.; Ng, A.; Jacobs, L.; Schwartz, C.; Virgo, K.S.; Hagerty, K.L.; Somerfield, M.R.; Vaughn, D.J.; Panel, A.C.S.E. ASCO Cancer Survivorship Expert Panel. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J. Clin. Oncol., 2007, 25(25), 3991-4008.
[http://dx.doi.org/10.1200/JCO.2007.10.9777] [PMID: 17577017]
[6]
Feola, M.; Garrone, O.; Occelli, M.; Francini, A.; Biggi, A.; Visconti, G.; Albrile, F.; Bobbio, M.; Merlano, M. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int. J. Cardiol., 2011, 148(2), 194-198.
[http://dx.doi.org/10.1016/j.ijcard.2009.09.564] [PMID: 19945181]
[7]
Von Hoff, D.D.; Layard, M.W.; Basa, P.; Davis, H.L., Jr; Von Hoff, A.L.; Rozencweig, M.; Muggia, F.M. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med., 1979, 91(5), 710-717.
[http://dx.doi.org/10.7326/0003-4819-91-5-710] [PMID: 496103]
[8]
Keefe, D.L. Anthracycline-induced cardiomyopathy. Semin. Oncol., 2001, 28(4)(Suppl. 12), 2-7.
[http://dx.doi.org/10.1053/sonc.2001.26431] [PMID: 11552224]
[9]
Salazar-Mendiguchía, J.; González-Costello, J.; Roca, J.; Ariza-Solé, A.; Manito, N.; Cequier, A. Anthracycline-mediated cardiomyopathy: basic molecular knowledge for the cardiologist. Arch. Cardiol. Mex., 2014, 84(3), 218-223.
[http://dx.doi.org/10.1016/j.acmx.2013.08.006] [PMID: 25001055]
[10]
Plana, J.C.; Galderisi, M.; Barac, A.; Ewer, M.S.; Ky, B.; Scherrer-Crosbie, M.; Ganame, J.; Sebag, I.A.; Agler, D.A.; Badano, L.P.; Banchs, J.; Cardinale, D.; Carver, J.; Cerqueira, M.; DeCara, J.M.; Edvardsen, T.; Flamm, S.D.; Force, T.; Griffin, B.P.; Jerusalem, G.; Liu, J.E.; Magalhães, A.; Marwick, T.; Sanchez, L.Y.; Sicari, R.; Villarraga, H.R.; Lancellotti, P. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging, 2014, 15(10), 1063-1093.
[http://dx.doi.org/10.1093/ehjci/jeu192] [PMID: 25239940]
[11]
Blaes, A.H.; Rehman, A.; Vock, D.M.; Luo, X.; Menge, M.; Yee, D.; Missov, E.; Duprez, D. Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy. Vasc. Health Risk Manag., 2015, 11, 591-594.
[http://dx.doi.org/10.2147/VHRM.S89842] [PMID: 26648730]
[12]
Dodos, F.; Halbsguth, T.; Erdmann, E.; Hoppe, U.C. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin. Res. Cardiol., 2008, 97(5), 318-326.
[http://dx.doi.org/10.1007/s00392-007-0633-6] [PMID: 18193371]
[13]
Frères, P.; Bouznad, N.; Servais, L.; Josse, C.; Wenric, S.; Poncin, A.; Thiry, J.; Moonen, M.; Oury, C.; Lancellotti, P.; Bours, V.; Jerusalem, G. Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC Cancer, 2018, 18(1), 102.
[http://dx.doi.org/10.1186/s12885-018-4015-4] [PMID: 29378531]
[14]
D’hooge, J.; Heimdal, A.; Jamal, F.; Kukulski, T.; Bijnens, B.; Rademakers, F.; Hatle, L.; Suetens, P.; Sutherland, G.R. Regional strain and strain rate measurements by cardiac ultrasound: principles, implementation and limitations. Eur. J. Echocardiogr., 2000, 1(3), 154-170.
[http://dx.doi.org/10.1053/euje.2000.0031] [PMID: 11916589]
[15]
Ho, E.; Brown, A.; Barrett, P.; Morgan, R.B.; King, G.; Kennedy, M.J.; Murphy, R.T. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart, 2010, 96(9), 701-707.
[http://dx.doi.org/10.1136/hrt.2009.173997] [PMID: 20424152]
[16]
Fei, H.W.; Ali, M.T.; Tan, T.C.; Cheng, K.H.; Salama, L.; Hua, L.; Zeng, X.; Halpern, E.F.; Taghian, A.; MacDonald, S.M.; Scherrer-Crosbie, M. Left ventricular global longitudinal strain in HER-2 + breast cancer patients treated with anthracyclines and trastuzumab who develop cardiotoxicity is associated with subsequent recovery of left ventricular ejection fraction. Echocardiography, 2016, 33(4), 519-526.
[http://dx.doi.org/10.1111/echo.13168] [PMID: 26992012]
[17]
Lang, R.M.; Badano, L.P.; Mor-Avi, V.; Afilalo, J.; Armstrong, A.; Ernande, L.; Flachskampf, F.A.; Foster, E.; Goldstein, S.A.; Kuznetsova, T.; Lancellotti, P.; Muraru, D.; Picard, M.H.; Rietzschel, E.R.; Rudski, L.; Spencer, K.T.; Tsang, W.; Voigt, J.U. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging, 2015, 16(3), 233-270.
[http://dx.doi.org/10.1093/ehjci/jev014] [PMID: 25712077]
[18]
Swain, S.M.; Whaley, F.S.; Ewer, M.S. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer, 2003, 97(11), 2869-2879.
[http://dx.doi.org/10.1002/cncr.11407] [PMID: 12767102]
[19]
Shan, K.; Lincoff, A.M.; Young, J.B. Anthracycline-induced cardiotoxicity. Ann. Intern. Med., 1996, 125(1), 47-58.
[http://dx.doi.org/10.7326/0003-4819-125-1-199607010-00008] [PMID: 8644988]
[20]
Wojtacki, J.; Lewicka-Nowak, E.; Leśniewski-Kmak, K. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention--review of the literature. Med. Sci. Monit., 2000, 6(2), 411-420.
[PMID: 11208348]
[21]
Schmitz, K.H.; Prosnitz, R.G.; Schwartz, A.L.; Carver, J.R. Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. Cancer, 2012, 118(8)(Suppl.), 2270-2276.
[http://dx.doi.org/10.1002/cncr.27462] [PMID: 22488701]
[22]
Cardinale, D.; Colombo, A.; Lamantia, G.; Colombo, N.; Civelli, M.; De Giacomi, G.; Rubino, M.; Veglia, F.; Fiorentini, C.; Cipolla, C.M. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J. Am. Coll. Cardiol., 2010, 55(3), 213-220.
[http://dx.doi.org/10.1016/j.jacc.2009.03.095] [PMID: 20117401]
[23]
Thavendiranathan, P.; Poulin, F.; Lim, K.D.; Plana, J.C.; Woo, A.; Marwick, T.H. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: A systematic review. J. Am. Coll. Cardiol., 2014, 63(25 Pt A), 2751-2768.
[http://dx.doi.org/10.1016/j.jacc.2014.01.073] [PMID: 24703918]
[24]
Neilan, T.G.; Jassal, D.S.; Perez-Sanz, T.M.; Raher, M.J.; Pradhan, A.D.; Buys, E.S.; Ichinose, F.; Bayne, D.B.; Halpern, E.F.; Weyman, A.E.; Derumeaux, G.; Bloch, K.D.; Picard, M.H.; Scherrer-Crosbie, M. Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. Eur. Heart J., 2006, 27(15), 1868-1875.
[http://dx.doi.org/10.1093/eurheartj/ehl013] [PMID: 16717080]
[25]
Sawaya, H.; Sebag, I.A.; Plana, J.C.; Januzzi, J.L.; Ky, B.; Cohen, V.; Gosavi, S.; Carver, J.R.; Wiegers, S.E.; Martin, R.P.; Picard, M.H.; Gerszten, R.E.; Halpern, E.F.; Passeri, J.; Kuter, I.; Scherrer-Crosbie, M. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am. J. Cardiol., 2011, 107(9), 1375-1380.
[http://dx.doi.org/10.1016/j.amjcard.2011.01.006] [PMID: 21371685]
[26]
Mousavi, N.; Tan, T.C.; Ali, M.; Halpern, E.F.; Wang, L.; Scherrer-Crosbie, M. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines. Eur. Heart J. Cardiovasc. Imaging, 2015, 16(9), 977-984.
[http://dx.doi.org/10.1093/ehjci/jev113] [PMID: 25925220]
[27]
Kitayama, H.; Kondo, T.; Sugiyama, J.; Kurimoto, K.; Nishino, Y.; Kawada, M.; Hirayama, M.; Tsuji, Y. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients. Breast Cancer, 2017, 24(6), 774-782.
[http://dx.doi.org/10.1007/s12282-017-0778-8] [PMID: 28434150]
[28]
Ky, B.; Putt, M.; Sawaya, H.; French, B.; Januzzi, J.L., Jr; Sebag, I.A.; Plana, J.C.; Cohen, V.; Banchs, J.; Carver, J.R.; Wiegers, S.E.; Martin, R.P.; Picard, M.H.; Gerszten, R.E.; Halpern, E.F.; Passeri, J.; Kuter, I.; Scherrer-Crosbie, M. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J. Am. Coll. Cardiol., 2014, 63(8), 809-816.
[http://dx.doi.org/10.1016/j.jacc.2013.10.061] [PMID: 24291281]
[29]
Sawaya, H.; Sebag, I.A.; Plana, J.C.; Januzzi, J.L.; Ky, B.; Tan, T.C.; Cohen, V.; Banchs, J.; Carver, J.R.; Wiegers, S.E.; Martin, R.P.; Picard, M.H.; Gerszten, R.E.; Halpern, E.F.; Passeri, J.; Kuter, I.; Scherrer-Crosbie, M. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging, 2012, 5(5), 596-603.
[http://dx.doi.org/10.1161/CIRCIMAGING.112.973321] [PMID: 22744937]
[30]
Fallah-Rad, N.; Walker, J.R.; Wassef, A.; Lytwyn, M.; Bohonis, S.; Fang, T.; Tian, G.; Kirkpatrick, I.D.; Singal, P.K.; Krahn, M.; Grenier, D.; Jassal, D.S. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J. Am. Coll. Cardiol., 2011, 57(22), 2263-2270.
[http://dx.doi.org/10.1016/j.jacc.2010.11.063] [PMID: 21616287]
[31]
Romano, S.; Fratini, S.; Ricevuto, E.; Procaccini, V.; Stifano, G.; Mancini, M.; Di Mauro, M.; Ficorella, C.; Penco, M. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br. J. Cancer, 2011, 105(11), 1663-1668.
[http://dx.doi.org/10.1038/bjc.2011.439] [PMID: 22068815]
[32]
Cardinale, D.; Sandri, M.T.; Martinoni, A.; Tricca, A.; Civelli, M.; Lamantia, G.; Cinieri, S.; Martinelli, G.; Cipolla, C.M.; Fiorentini, C. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J. Am. Coll. Cardiol., 2000, 36(2), 517-522.
[http://dx.doi.org/10.1016/S0735-1097(00)00748-8] [PMID: 10933366]
[33]
Auner, H.W.; Tinchon, C.; Linkesch, W.; Tiran, A.; Quehenberger, F.; Link, H.; Sill, H. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann. Hematol., 2003, 82(4), 218-222.
[PMID: 12679885]
[34]
Lipshultz, S.E.; Lipsitz, S.R.; Mone, S.M.; Goorin, A.M.; Sallan, S.E.; Sanders, S.P.; Orav, E.J.; Gelber, R.D.; Colan, S.D. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N. Engl. J. Med., 1995, 332(26), 1738-1743.
[http://dx.doi.org/10.1056/NEJM199506293322602] [PMID: 7760889]
[35]
Lipshultz, S.E.; Rifai, N.; Dalton, V.M.; Levy, D.E.; Silverman, L.B.; Lipsitz, S.R.; Colan, S.D.; Asselin, B.L.; Barr, R.D.; Clavell, L.A.; Hurwitz, C.A.; Moghrabi, A.; Samson, Y.; Schorin, M.A.; Gelber, R.D.; Sallan, S.E. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N. Engl. J. Med., 2004, 351(2), 145-153.
[http://dx.doi.org/10.1056/NEJMoa035153] [PMID: 15247354]
[36]
Kilickap, S.; Barista, I.; Akgul, E.; Aytemir, K.; Aksoyek, S.; Aksoy, S.; Celik, I.; Kes, S.; Tekuzman, G. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann. Oncol., 2005, 16(5), 798-804.
[http://dx.doi.org/10.1093/annonc/mdi152] [PMID: 15774486]
[37]
Horacek, J.M.; Vasatova, M.; Pudil, R.; Tichy, M.; Zak, P.; Jakl, M.; Jebavy, L.; Maly, J. Biomarkers for the early detection of anthracycline-induced cardiotoxicity: Current status. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 2014, 158(4), 511-517.
[http://dx.doi.org/10.5507/bp.2014.004] [PMID: 24457832]
[38]
deFilippi, C.R.; de Lemos, J.A.; Christenson, R.H.; Gottdiener, J.S.; Kop, W.J.; Zhan, M.; Seliger, S.L. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA, 2010, 304(22), 2494-2502.
[http://dx.doi.org/10.1001/jama.2010.1708] [PMID: 21078811]
[39]
Tsutamoto, T.; Kawahara, C.; Yamaji, M.; Nishiyama, K.; Fujii, M.; Yamamoto, T.; Horie, M. Relationship between renal function and serum cardiac troponin T in patients with chronic heart failure. Eur. J. Heart Fail., 2009, 11(7), 653-658.
[http://dx.doi.org/10.1093/eurjhf/hfp072] [PMID: 19502379]
[40]
Saunders, J.T.; Nambi, V.; de Lemos, J.A.; Chambless, L.E.; Virani, S.S.; Boerwinkle, E.; Hoogeveen, R.C.; Liu, X.; Astor, B.C.; Mosley, T.H.; Folsom, A.R.; Heiss, G.; Coresh, J.; Ballantyne, C.M. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation, 2011, 123(13), 1367-1376.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.005264] [PMID: 21422391]
[41]
Otsuka, T.; Kawada, T.; Ibuki, C.; Seino, Y. Association between high-sensitivity cardiac troponin T levels and the predicted cardiovascular risk in middle-aged men without overt cardiovascular disease. Am. Heart J., 2010, 159(6), 972-978.
[http://dx.doi.org/10.1016/j.ahj.2010.02.036] [PMID: 20569708]
[42]
Mavinkurve-Groothuis, A.M.; Marcus, K.A.; Pourier, M.; Loonen, J.; Feuth, T.; Hoogerbrugge, P.M.; de Korte, C.L.; Kapusta, L. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): A prospective study. Eur. Heart J. Cardiovasc. Imaging, 2013, 14(6), 562-569.
[http://dx.doi.org/10.1093/ehjci/jes217] [PMID: 23109647]
[43]
Ferraro, M.P.; Gimeno-Vazquez, E.; Subirana, I.; Gómez, M.; Díaz, J.; Sánchez-González, B.; García-Pallarols, F.; Martínez, L.; Ble, M.; Molina, L.; Belarte, L.C.; Abella, E.; Elosua, R.; Comín-Colet, J.; Salar, A. Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification. Eur. J. Haematol., 2019, 102(6), 509-515.
[http://dx.doi.org/10.1111/ejh.13234] [PMID: 30972815]
[44]
Armenian, S.; Bhatia, S. Predicting and Preventing Anthracycline-Related Cardiotoxicity. Am. Soc. Clin. Oncol. Educ. Book, 2018, 38, 3-12.
[http://dx.doi.org/10.1200/EDBK_100015] [PMID: 30231396]


open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 1
Year: 2020
Published on: 26 February, 2020
Page: [74 - 83]
Pages: 10
DOI: 10.2174/1871529X19666190912150942

Article Metrics

PDF: 43
HTML: 6



Related Article(s)

Most Downloaded Article(s)